High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER(+) breast cancer.

Palafox M, Monserrat L, Bellet M, Villacampa G, Gonzalez-Perez A, Oliveira M, Braso-Maristany F, Ibrahimi N, Kannan S, Mina L, Herrera-Abreu MT, Odena A, Sanchez-Guixe M, Capelan M, Azaro A, Bruna A, Rodriguez O, Guzman M, Grueso J, Viaplana C, Hernandez J, Su F, Lin K, Clarke RB, Caldas C, Arribas J, Michiels S, Garcia-Sanz A, Turner NC, Prat A, Nuciforo P, Dienstmann R, Verma CS, Lopez-Bigas N, Scaltriti M, Arnedos M, Saura C, Serra V
Nat Commun. 2022 Sep 7;13(1):5258. doi: 10.1038/s41467-022-32828-6. PubMed Article

Plasmids from Article

No plasmids are currently publicly available from Addgene for this article.